Insider buying last 90 days
No open-market insider purchases were filed for PTCT in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
PTC Therapeutics' board has authorized a share repurchase program of up to $500 million, announced alongside continued attention on Sephience's launch, which has been offsetting declines in legacy products. Commentary this week has been mixed: one view describes the stock as roughly fairly valued around a P/S ratio of 5.0x, while another rates it Hold, bordering on Sell, with a fair value estimate near $52 per share against its own cited price. Shareholders remain down 20.7% year-to-date according to one recap, even as the company has pointed to record revenue and raised guidance earlier in the year.
PTCT closed at $65.03, down 0.6%, sitting between its 50-day average of $64.67 and 200-day average of $70.40. The GekkoIndex reads 55.5, placing the stock in the Neutral zone, down 6.9 over five days. Price sits 17.7% below Gekko Fair Value of $78.97. Over the past three and six months, shares have declined 11.8% and 15.4% respectively, with a 52-week range of $58.80 to $90.87.
The next earnings report is scheduled for 18 February 2027, 100 days out and beyond a typical 20-day holding window. No insider, Congress, or unusual options activity appears in the current windows. Seasonally, the next 20 trading days have averaged a 10.7% return over 5 years, rising in 4 of them. Analyst coverage from 12 firms shows 10 Buy and 2 Hold ratings, with a consensus target of $100.47. Upcoming investor conference appearances on 16 November and 1 December are also worth noting.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
PTC Therapeutics scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
Below 50 and 200-day
Close $63.49 is below the 50-day ($64.12) and 200-day ($70.16) averages, and the 50-day is below the 200-day.
See the chart58, Neutral
Reading 58 is in the Neutral zone.
See the GekkoIndex19.1% below
Price is 19.1% below Gekko Fair Value (more than 5% below).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 95 days
Next report Feb 18, 2027, 95 days away — outside a typical 20-trading-day hold.
See earnings+9.5% on average
From this point in the calendar, the next 20 trading days averaged +9.5% over 5 years, rising in 4 of them.
See seasonalityA description of current data, not a recommendation. How this page works
PTC Therapeutics closed at $63.49 on Nov 13, 2026, −15.3% over the past year, inside a 52-week range of $58.80 to $90.87.
Use the left and right arrow keys to read daily values.
Put PTCT on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
PTC Therapeutics develops medicines for people with rare genetic disorders, working across early research, preclinical studies and clinical trials. The company is known for treatments aimed at Duchenne muscular dystrophy, including Translarna and Emflaza, which reach patients in the European Economic Area, the United States, and, in the case of Translarna, Brazil and Russia for a nonsense mutation form of the disease.
Beyond its Duchenne-focused products, the company sells Tegsedi and Waylivra for other rare conditions across Latin America and the Caribbean, and distributes Evrysdi in Brazil for spinal muscular atrophy in patients two months and older. It also uses a proprietary splicing platform to advance PTC518, a candidate being studied for Huntington's disease. Its work is supported by collaborations, including ones with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., the Spinal Muscular Atrophy Foundation, and Akcea Therapeutics, Inc., the last of which relates to commercializing Tegsedi and Waylivra in Latin America and the Caribbean.
PTC Therapeutics was established in 1998 and is headquartered in South Plainfield, New Jersey. Its shares are listed on the NASDAQ under the ticker PTCT.
PTC Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 58, in the Neutral zone, up 3.3 points over five sessions.
Up 3.3 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 33 | +2.9% | +6.3% | ||
| Accumulation | 204 | +1.7% | +5.3% | ||
| Neutral (current zone) | 414 | +0.6% | +2.4% | ||
| Distribution | 50 | −1.7% | −0.8% | ||
| Selling | 1 | Too few readings yet | |||
Average PTCT share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
PTC Therapeutics trades 19.1% below Gekko Fair Value of $78.46, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what PTC Therapeutics shares are worth, recalculated every trading day.
$78.46
Gekko Fair Value, Nov 14, 2026
19.1% Undervalued
At the end of Aug 2026 the price was 23.9% below the estimate.
No open-market insider purchases were filed for PTC Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for PTCT in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in PTCT were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
From company filings.
0of the funds Gekko tracks hold PTCT.
PTC Therapeutics reports on Feb 18, 2027, after the close (95 days away), and beat the EPS estimate in 7 of its last 8 reports.
Feb 18, 2027
Expected after the close, 95 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 30, 2026 | $0.92 est $0.24 | $360.5M est $298.6M | −8.7% |
| May 7, 2026 | −$0.03 est −$0.45 | $272.6M est $217.4M | +10.7% |
| Feb 19, 2026 | −$1.67 est −$0.21 | $164.7M est $279.5M | +2.5% |
| Nov 4, 2025 | $0.20 est −$1.19 | $211.0M est $281.5M | +5.7% |
| Aug 7, 2025 | −$0.83 est −$1.07 | $178.9M est $191.5M | −11.6% |
| May 6, 2025 | $10.04 est −$1.08 | $1.18B est $372.6M | +0.3% |
| Feb 27, 2025 | −$0.85 est −$1.12 | $213.2M est $232.4M | +8.4% |
| Nov 7, 2024 | −$1.39 est −$1.44 | $196.8M est $190.5M | +2.5% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for PTC Therapeutics is $100.47, +58.2% from the last close, from 12 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 12 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 2 | Barclays | $122 | +92.2% |
| Nov 2 | Citi | $109 | +71.7% |
| Nov 2 | J.P. Morgan | $92 | +44.9% |
| Oct 30 | Wells Fargo | $112 | +76.4% |
| Oct 30 | UBS | $90 | +41.8% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, PTC Therapeutics averaged +9.5% across the last 5 years, rising in 4 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +2.8% | 4 of 5 |
| Next 10 trading days | +4.5% | 4 of 5 |
| Next 15 trading days | +8.3% | 4 of 5 |
| Next 20 trading days | +9.5% | 4 of 5 |
| Next 30 trading days | +8.7% | 4 of 5 |
For scale, PTCT’s typical 20-trading-day move in either direction is about 8.7%.
PTC Therapeutics’s market cap is $5.30B and revenue of $1.16B over the last twelve months.
2 headlines about PTC Therapeutics from the past week, newest first, each linking to the publisher.
PTC Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 24.0% above |
| JNJJohnson & Johnson | Neutral | 4.4% above |
| ABBVAbbVie | Neutral | 23.7% above |
| MRKMerck | Neutral | 8.2% below |
| AZNAstraZeneca | Neutral | 34.6% below |
| PFEPfizer | Accumulation | 8.9% below |
A peer links to its own page where one exists.
PTC Therapeutics’s market cap is $5.30B at the Nov 13, 2026 close of $63.49, with 83.54M shares outstanding.
The consensus analyst 12-month price target for PTC Therapeutics is $100.47, +58.2% from the last close. Of the 12 firms that rated the stock in the last 90 days, 10 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate PTC Therapeutics is undervalued: the Nov 13, 2026 close of $63.49 is 19.1% below Gekko Fair Value of $78.46. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
PTC Therapeutics is expected to report on Feb 18, 2027, after the market closes (95 days away). Analysts expect earnings of $0.35 per share on revenue of $330.4M. PTC Therapeutics beat the earnings estimate in 7 of its last 8 reports, moving 6.3% on average across the report.
PTC Therapeutics’s 52-week high is $90.87 and its 52-week low is $58.80; it closed at $63.49 on Nov 13, 2026, −15.3% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (fair value, earnings risk and seasonality), 1 as mixed (gekkoindex) and 1 as a headwind (trend). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.